Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017 (2017), Article ID 1286198, 6 pages
Research Article

Association between Gastric Cancer Risk and Serum Helicobacter pylori Antibody Titers

1Department of Gastroenterology, Oita University Faculty of Medicine, Oita, Japan
2Takada Chuo Hospital, Oita, Japan
3The Bungotakada City Medical Association, Oita, Japan
4Oita Kouseiren Tsurumi Hospital, Oita, Japan
5Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Oita, Japan

Correspondence should be addressed to Kazuhiro Mizukami

Received 3 March 2017; Revised 24 April 2017; Accepted 14 May 2017; Published 11 June 2017

Academic Editor: Tatsuya Toyokawa

Copyright © 2017 Mitsutaka Shuto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background/Aims. It is difficult to confirm the accurate cutoff value to diagnose Helicobacter pylori (Hp) infection using commercial serology kits. It is reported that there were many cases with present/past infection that even the serum Hp-IgG antibody (HpAb) titers were below the cutoff value (e.g., 10 U/mL for E-Plate®), suggesting that we might overlook many gastric cancer (GC). We investigated an association between gastric cancer risk and serum Helicobacter pylori antibody titers. Methods. We conducted a primary screening between 2014 and 2015. We performed gastroendoscopy if HpAb titers were ≥3.0 U/mL (i.e., more than measurable limit, E-Plate). These patients were divided into two groups: HpAb = 3.0–9.9 U/mL (“negative-high” group) and HpAb ≥ 10 U/mL; cutoff value (“over-10 U/mL” group). Hp infection status was investigated, and the number of GC patients was counted. Results. Among the 3321 subjects in the primary screening, 56.9% (1891/3321) showed HpAb titers ≥3.0 U/mL; 1314 patients underwent gastroendoscopy. Ten were GC. 421 patients were “negative-high” group; two were GC. After evaluating 381 patients for Hp infection, 22.6%/60.6% was with present/past infection among the “negative-high” group. Conclusion. We also found a correlation between HpAb titers and Hp infection status. “Negative-high” group has a risk of GC.